BL
BRENNA LEAMER
F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES · WASHINGTON, DC · registered since 2024
Registered · LDAActive
At a glance
Registered since
2024
Senate LDA system
Clients
1
last 3 years
Filings
5
5 agencies contacted
Activity
filings by quarter
Works on
Specific issues
(FOR) PEPFAR Reauthorization / FY2026 Appropriations for PEPFAR laboratory services and testing
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Clinical Lab Fee Schedule reform and Medicare coverage of FDA approved breakthrough diagnostics and innovative diagnostics
(MMM) Clinical Lab Fee Schedule reform and Medicare coverage of FDA approved breakthrough diagnostics and innovative diagnostics (preeclampsia)
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act. Issues related to the regulation of diagnostics
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and S. 5349/ H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to the coverage of neurology markers on the Clinical Lab Fee Schedule